SCHEMBL222602

SCHEMBL222602

Clc1cccc(OCc2cn(C(c3ccccc3)(c3ccccc3)c3ccccc3)cn2)c1Cl

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MRGPRX4 Q96LA9 1/20 0.41
SIRT2 Q8IXJ6 14/20 0.40
KDM4E B2RXH2 1/20 0.39
NMBR P28336 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
ALDH1A1 P00352 1/20 0.36
MEN1 O00255 1/20 0.36
SLC22A1 O15245 1/20 0.36
KCNN4 O15554 1/20 0.36
NR1I2 O75469 1/20 0.36
GMNN O75496 1/20 0.36
USP2 O75604 1/20 0.36
TRPM2 O94759 1/20 0.36
ABCB11 O95342 1/20 0.36
EGFR P00533 1/20 0.36
CA2 P00918 1/20 0.36
LMNA P02545 1/20 0.36
NR3C1 P04150 1/20 0.36
ERBB2 P04626 1/20 0.36
TP53 P04637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL224236 0.82 SIRT2 (0.43) SIRT2MAPTDRD2MAPK1TDP1
SCHEMBL6674214 0.78 KCNH2 (0.46) SIRT2CYP19A1KCNH2CYSLTR1
SCHEMBL10818574 0.76 SIRT2 (0.43) SIRT2NMBR
SCHEMBL14289994 0.76 SIRT2 (0.46) SIRT2NMBRMAPT
SCHEMBL759 0.73 SIRT2 (0.45) SIRT2NMBRSMN1; SMN2MEN1SLC22A1
SCHEMBL14901171 0.73 SIRT2 (0.46) SIRT2NMBR
SCHEMBL5203299 0.72 MAOB (0.50) SIRT2TP53CYP3A4TSHRMAOB
Hydrochloric Acid SCHEMBL6926362 0.72 SIRT2 (0.44) SIRT2NMBRSMN1; SMN2MEN1SLC22A1
SCHEMBL4855420 0.71 SIRT2 (0.48) SIRT2SMN1; SMN2ALDH1A1
SCHEMBL1097103 0.71 SIRT2 (0.42) SIRT2NMBRSMN1; SMN2MEN1SLC22A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399463-B2 Imidazole derivatives HOFFMANN-LA ROCHE INC. (US) 2013-03-19 US disclosed
US-8399463-B2 Imidazole derivatives HOFFMANN-LA ROCHE INC. (US) 2013-03-19 US disclosed
US-8399463-B2 Imidazole derivatives HOFFMANN-LA ROCHE INC. (US) 2013-03-19 US disclosed
US-20120004230-A1 IMIDAZOLE DERIVATIVES GALLEY GUIDO (DE) 2012-01-05 US disclosed
US-20120004230-A1 IMIDAZOLE DERIVATIVES GALLEY GUIDO (DE) 2012-01-05 US disclosed
US-20120004230-A1 IMIDAZOLE DERIVATIVES GALLEY GUIDO (DE) 2012-01-05 US disclosed
US-20100204233-A1 IMIDAZOLE DERIVATIVES GALLEY GUIDO 2010-08-12 US disclosed
US-20100204233-A1 IMIDAZOLE DERIVATIVES GALLEY GUIDO 2010-08-12 US disclosed
US-20100204233-A1 IMIDAZOLE DERIVATIVES GALLEY GUIDO 2010-08-12 US disclosed
EP-2094668-A2 4-IMIDAZOLINES AS TAAR'S LIGANDS F. Hoffmann-Roche AG (CH) 2009-09-02 EP disclosed
WO-2008074679-A2 4-IMIDAZOLINES AS TAAR'S LIGANDS F. HOFFMANN-LA ROCHE AG (CH) 2008-06-26 WO disclosed
WO-2008074679-A2 4-IMIDAZOLINES AS TAAR'S LIGANDS F. HOFFMANN-LA ROCHE AG (CH) 2008-06-26 WO disclosed
US-20080146523-A1 IMIDAZOLE DERIVATIVES HOFFMANN-LA ROCHE INC. 2008-06-19 US disclosed
US-20080146523-A1 IMIDAZOLE DERIVATIVES HOFFMANN-LA ROCHE INC. 2008-06-19 US disclosed
US-20080146523-A1 IMIDAZOLE DERIVATIVES HOFFMANN-LA ROCHE INC. 2008-06-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100204233-A1 IMIDAZOLE DERIVATIVES TAAR1, TAAR5, TACR1 MRGPRX4 93/4885SIRT2 3927/4885KDM4E 3695/4885
US-20120004230-A1 IMIDAZOLE DERIVATIVES TAAR1, TAAR5, TACR1 MRGPRX4 93/4885SIRT2 3927/4885KDM4E 3695/4885
US-20080146523-A1 IMIDAZOLE DERIVATIVES TAAR1, TAAR5, TACR1 MRGPRX4 93/4885SIRT2 3927/4885KDM4E 3695/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.